LXRX Lexicon Pharmaceuticals (LXRX) Q4 Loss Narrows to $0.04 Per Share Despite 79% Revenue Plunge to $5.5M 2 weeks ago Lexicon narrows Q4 loss to $0.04 per share from $0.09 year-ago, but revenue plunges 79% to $5.5M amid commercialization challenges. LXRX Reports Mixed Q4 Results: Loss Improves to $0.04 Per Share But Revenue Crashes 79% YoY 2 weeks ago Lexicon narrows Q4 loss to $0.04 per share, down 55.6% YoY, but revenue plunges 79% to $5.5M amid biotechnology sector…